Breast Imaging

What Breast Cancer Screening Is Best for Transmasculine Patients Without Top Surgery?

·
What Breast Cancer Screening Is Best for Transmasculine Patients Without Top Surgery?

A 42-year-old transmasculine patient is in your primary care clinic for an annual wellness visit. He has been on testosterone therapy for over a decade and underwent a reduction mammoplasty eight years ago but did not have a full bilateral mastectomy. As you review his preventive health needs, the topic of breast cancer screening arises. Given the altered chest anatomy and hormonal context, you need to determine the most appropriate imaging modality to order. This article provides a detailed clinical workflow for this specific scenario, guiding you through the American College of Radiology (ACR) recommendations. For this patient, the ACR rates Digital breast tomosynthesis screening as Usually appropriate.

Who Fits This Clinical Scenario for Breast Cancer Screening?

This guidance applies to a specific patient population: transmasculine (female-to-male) individuals who are 40 years of age or older, at average risk for breast cancer (less than 15% lifetime risk), and who have residual breast tissue. This includes patients who have had no chest surgery as well as those who have undergone reduction mammoplasty. The key inclusion criterion is the presence of sufficient glandular tissue to warrant screening, as this tissue remains susceptible to malignant transformation.

It is critical to distinguish this scenario from others that require a different approach. This workflow does not apply to:

  • Transmasculine patients with bilateral mastectomies (“top surgery”): These individuals have minimal residual breast tissue, and routine screening mammography is generally not performed. The risk of breast cancer is substantially reduced, though not zero, and management is typically focused on physical examination.
  • Transmasculine patients at high risk: Individuals with a known genetic mutation (e.g., BRCA1/2), a strong family history suggesting a lifetime risk of 20% or more, or a history of chest wall radiation require a high-risk screening protocol, which often involves breast MRI.
  • Transfeminine (male-to-female) patients: Screening guidelines for transfeminine individuals are distinct, based on their duration of hormone therapy and other risk factors.

Correctly identifying the patient’s surgical history, hormonal status, and overall risk profile is the essential first step to ensure the appropriate screening strategy is selected.

What Diagnoses Are You Working Up in This Scenario?

As this is a screening scenario, the primary goal is the early detection of asymptomatic breast cancer before it becomes clinically apparent. The imaging study is designed to identify suspicious findings that could represent a range of pathologies, from pre-invasive to invasive disease. The differential considerations in this context include:

Ductal Carcinoma In Situ (DCIS): This is a non-invasive or pre-invasive form of breast cancer where abnormal cells are contained within the milk ducts. On mammography, DCIS often presents as suspicious microcalcifications. Detecting cancer at this early stage is a major objective of screening, as it is highly curable.

Invasive Ductal Carcinoma (IDC): The most common type of invasive breast cancer, IDC begins in a milk duct but grows into the surrounding breast tissue. From there, it has the potential to metastasize. Mammography can detect IDC as a spiculated mass, architectural distortion, or suspicious calcifications.

Invasive Lobular Carcinoma (ILC): Less common than IDC, this cancer begins in the milk-producing glands (lobules). ILC can be more challenging to detect on mammography because it often grows in a diffuse pattern without forming a distinct lump, sometimes presenting as subtle architectural distortion.

Benign Breast Conditions: Screening mammography will also identify numerous benign findings that do not require intervention but may necessitate further workup to confirm their benign nature. These include fibroadenomas, cysts, and benign calcifications. Distinguishing these from malignant lesions is a key function of the radiologist and subsequent diagnostic evaluation.

Why Is Digital Breast Tomosynthesis Screening the Recommended Study for This Presentation?

The ACR Appropriateness Criteria rate Digital breast tomosynthesis screening as Usually appropriate for this clinical scenario. This recommendation is based on the technology’s superior ability to detect cancers and reduce the rate of false positives compared to conventional 2D mammography, which is also rated Usually appropriate.

Digital breast tomosynthesis (DBT), often called 3D mammography, acquires multiple low-dose images of the breast from different angles, which are then reconstructed into a three-dimensional dataset. This allows the radiologist to examine the breast tissue in thin slices, minimizing the effect of overlapping tissue that can obscure cancers or mimic abnormalities on 2D images. This is particularly advantageous in transmasculine patients who have had reduction mammoplasty, as scar tissue and altered tissue distribution can make standard 2D mammogram interpretation more complex. DBT helps differentiate true lesions from post-surgical changes and summation artifact.

In contrast, other imaging modalities are not recommended for routine screening in this average-risk population:

  • US breast is rated Usually not appropriate for screening. While ultrasound is an essential tool for diagnostic workups (e.g., evaluating a palpable lump or a mammographic finding), it is not sensitive or specific enough to be used as a primary screening tool for the entire breast in average-risk individuals. It has a higher rate of false positives and is highly operator-dependent.
  • MRI breast without and with IV contrast is also rated Usually not appropriate for screening in this context. Breast MRI is a highly sensitive test, but its use is reserved for high-risk screening (e.g., patients with >20% lifetime risk) due to its higher cost, lower specificity (leading to more benign biopsies), and need for intravenous contrast.

The radiation dose for both DBT and standard mammography is low (ACR Radiation Relative Level ☢☢, 0.1-1 mSv), and the benefits of early cancer detection are considered to far outweigh the minimal risk. For detailed technical specifications on performing the study, refer to established guidelines for Screening Mammography with DBT.

What’s Next After Digital Breast Tomosynthesis Screening? Downstream Workflow

The results of the screening DBT, reported using the Breast Imaging Reporting and Data System (BI-RADS) score, will dictate the next steps in the clinical workflow.

  • Negative or Benign Result (BI-RADS 1 or 2): If the study is negative or shows clearly benign findings, no further immediate action is needed. The patient should be advised to continue with routine annual screening mammography.
  • Incomplete Result (BI-RADS 0): This indicates that the initial screening images are insufficient for a final assessment and additional imaging is required. The patient will be recalled for a diagnostic workup, which typically includes diagnostic mammography (with spot compression or magnification views) and/or a targeted breast ultrasound to clarify the finding seen on the screening study.
  • Probably Benign Result (BI-RADS 3): This category is for a finding that has a very high probability of being benign (<2% risk of malignancy). The standard recommendation is a short-interval follow-up, typically with a mammogram of the affected breast in six months, to ensure stability.
  • Suspicious or Highly Suggestive of Malignancy (BI-RADS 4 or 5): These findings warrant tissue sampling. The patient should be referred for a biopsy, most commonly a percutaneous core needle biopsy, to establish a definitive diagnosis. The specific biopsy method (stereotactic, ultrasound-guided, or MRI-guided) will depend on how the lesion is best visualized.

A clear plan for follow-up based on the BI-RADS assessment ensures that patients with normal results return to screening and those with abnormal findings proceed efficiently to diagnostic evaluation and potential treatment.

Pitfalls to Avoid (and When to Get Help)

Several potential pitfalls can occur when managing breast cancer screening for this specific patient population. First, do not assume that a history of reduction mammoplasty eliminates the need for screening; significant amounts of glandular tissue often remain. Second, be aware that post-surgical scarring can create mammographic densities that mimic malignancy, reinforcing the value of DBT and comparison with prior imaging. Third, ensure the imaging facility is experienced in mammography for patients with surgically altered breasts, as proper positioning is crucial for an accurate study.

Finally, a common error is miscalculating a patient’s lifetime risk. If a detailed family history reveals multiple first-degree relatives with breast or ovarian cancer, or other high-risk features, the patient may not be “average risk” and could require referral to a high-risk clinic for genetic counseling and consideration of supplemental screening with MRI. If there is any uncertainty about risk assessment or the interpretation of imaging results, consultation with a breast imaging specialist is the appropriate next step.

Related ACR Topics and Tools

For a comprehensive overview of imaging recommendations across all patient presentations within this topic, please consult the parent guide. Additional GigHz tools are available to assist in clinical decision-making and patient communication.

Frequently Asked Questions

Does long-term testosterone therapy reduce breast cancer risk in transmasculine individuals?

While testosterone therapy leads to the cessation of menses and atrophy of breast glandular tissue, it does not eliminate breast cancer risk. The breast tissue that remains is still susceptible to developing cancer. Current guidelines recommend screening based on the presence of breast tissue and age, similar to cisgender women, not based on hormone status alone.

How does a prior reduction mammoplasty affect the mammogram procedure and interpretation?

Reduction mammoplasty alters the breast’s architecture and creates scar tissue. This can make mammographic positioning more challenging and interpretation more complex. It is crucial for the patient to inform the technologist of their surgical history. Radiologists will look for signs of architectural distortion, but DBT (3D mammography) is particularly helpful in distinguishing post-surgical scarring from a true underlying lesion.

Should this patient also perform regular self-exams?

Yes, breast/chest self-awareness is encouraged. Patients should be familiar with the normal look and feel of their chest tissue, including any post-surgical changes, and report any new or persistent changes, such as a new lump, skin dimpling, or nipple discharge, to their healthcare provider promptly. This is complementary to, not a replacement for, screening mammography.

If this patient were under 40, would the recommendation change?

Yes. For average-risk transmasculine patients with retained breast tissue who are under 40, routine screening mammography is generally not recommended, mirroring guidelines for average-risk cisgender women. Screening typically begins at age 40. However, if a patient in their 30s is found to be at high risk (e.g., due to a new family history or genetic finding), a different, risk-stratified screening protocol would apply.

Why is MRI not used for screening in this average-risk scenario?

Breast MRI is a very sensitive test but is not specific, meaning it has a higher rate of false positives that can lead to unnecessary anxiety and benign biopsies. Its use is reserved for screening individuals at high risk (e.g., >20% lifetime risk) where the higher pre-test probability of cancer justifies the trade-offs. For an average-risk patient, DBT provides the best balance of cancer detection and manageable recall rates.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026